CD34+ Transplants for Myeloid Malignancies

StatusNot Yet Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 6 months later Jun 2033 → Jan 2034
Primary endpoints removed 5 → 1 primary endpoints
Enrollment reduced 50% 100 → 50 participants
See other at-risk trials from Guenther Koehne

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Jun 2033 to Jan 2034 Show 10 more changesShow less
    • Primary endpoint(s) modified
    • Enrollment reduced: 100 → 50 participants
    • Start date: Jun 2026 to Jan 2027
    • Interventions modified
    • Trial arms changed: 2 → 1
    • Eligibility criteria expanded, about 233 words
    • Secondary endpoints: 1 to 5
    • Study site revised
    • Publications: details revised at 4 of 4 entries
    • Study title shortened, about 1 word
  2. Primary and study completion dates: Sep 2032 to Jun 2033
    • Start date: Jan 2026 to Jun 2026
    v13
  3. Start date: Sep 2025 to Jan 2026v12
  4. Start date: Mar 2025 to Sep 2025
    • Primary and study completion dates: Mar 2032 to Sep 2032
    v11
  5. Start date: Oct 2024 to Mar 2025
    • Primary and study completion dates: Oct 2031 to Mar 2032
    v10
Show 8 earlier versionsHide 8 earlier versions
  1. Start date: Jun 2024 to Oct 2024
    • Primary and study completion dates: Jun 2031 to Oct 2031
    v9
  2. Lead sponsor: Baptist Health South Florida to Guenther Koehne
    • Start date: Mar 2024 to Jun 2024
    • Primary and study completion dates: Mar 2031 to Jun 2031
    v8
  3. Start date: Dec 2023 to Mar 2024
    • Primary and study completion dates: Dec 2030 to Mar 2031
    v7
  4. Start date: Aug 2023 to Dec 2023
    • Primary and study completion dates: Aug 2030 to Dec 2030
    v6
  5. Start date: Jun 2023 to Aug 2023
    • Primary and study completion dates: Jun 2030 to Aug 2030
    v5
  6. Start date: Apr 2023 to Jun 2023
    • Primary and study completion dates: Mar 2030 to Jun 2030
    v4
  7. Start date: Jan 2023 to Apr 2023
    • Primary and study completion dates: Jan 2030 to Mar 2030
    v3
  8. Start date: Oct 2022 to Jan 2023
    • Primary and study completion dates: Oct 2029 to Jan 2030
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This study will evaluate whether processing blood stem cell transplants using an investigational device (the CliniMACS system) results in less complications for patients undergoing transplant for treatment of a blood malignancy (cancer) or blood disorder.
Trial Details
NCT Number NCT05565105
Lead Sponsor Guenther Koehne
Conditions
(from sponsor)		 Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute
Related terms Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov